Related Experiment Video
Updated: May 2, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
The temporospatial evolution of neuritic plaque-related and independent tauopathies: implications for dementia
Donald R Royall1, Raymond F Palmer2
1Department of Psychiatry, The University of Texas Health Science Center, San Antonio, TX, USA Department of Medicine, The University of Texas Health Science Center, San Antonio, TX, USA Department of Family & Community Medicine, The University of Texas Health Science Center, San Antonio, TX, USA South Texas Veterans' Health System Audie L. Murphy Division GRECC, San Antonio, TX, USA.
Abstract:
Neuritic plaque (NP) formation can be dated in vivo. This analysis attempts to "date" the progression of neurofibrillary tangles (NFT) using the spatial distribution of NP as a reference. Autopsy data from 471 participants in the Honolulu-Asia Aging Study (HAAS) were combined into latent factor measures of NFT and NP counts. The variance in "early" and "late" NP pathology was used to estimate the spatial distribution of "early" and "late" NFT formation. A third latent factor representing "non-NP-related NFT" was also constructed. "Early" NP and "late" NP correlated significantly with objectively early and later cognitive performance, respectively. In contrast to our expectations, neocortical NFT correlated best with "early" NP pathology, while NFT in allocortical structures correlated best with "late" NP pathology. Therefore, the NP-related fraction of NFT appears to be co-localized spatially with NP. However, since the latter evolve corticofugally in time, this suggests that NP-related NFT do so as well. Corticotropic NFT formation must therefore be either unrelated to NP formation, a temporally distinct process, or both.
Related Concept Videos
Dementia l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Dementia
The progression of dementia is generally gradual....
Alzheimer's Disease: Treatment

